Micro Dosing Wegovy: the Titration Logic Behind Lower Starting Doses

Step 1: Why the schedule starts so low

Wegovy (semaglutide) is a GLP-1 receptor agonist that slows gastric emptying and reduces appetite. Both of those effects can produce nausea, especially in the first weeks. The 0.25 mg starting dose exists almost entirely to give your digestive system time to adjust, not to produce significant weight loss. The NHS semaglutide medicines page describes 0.25 mg as an introductory dose used for four weeks before the first increase.

Most people notice the strongest nausea and fatigue during the first two to four weeks and again after each dose step. Knowing this matters: staying at 0.25 mg longer than the standard schedule is sometimes presented online as a clever workaround, but it is really just an extended tolerability phase. Some prescribers will sanction it where side effects are genuinely limiting. Others will not, depending on the clinical picture.

You can read more about how each weekly injection dose is structured on our Wegovy dose guide.

Step 2: Where the phrase 'micro dose' comes from

The licensed Wegovy schedule has no formal micro-dose tier, the term comes from patient forums and social media, usually meaning one of two things. First, some people split or partially depress a dose to inject less than the pen delivers. This is not recommended, not clinically validated and not covered by the manufacturer's safety data. Second, and more legitimately, prescribers sometimes hold patients at 0.25 mg or 0.5 mg beyond the standard four-week window because GI side effects have been difficult. That is a clinical decision, documented and reviewed.

If you have been reading about micro dosing Wegovy as a strategy to avoid side effects while still losing weight, the honest picture is nuanced. Lower doses do produce some appetite suppression in many people, which is why questions like whether weight loss is possible on the starting dose come up so often. But the STEP 1 trial, published in the New England Journal of Medicine, found the full 2.4 mg maintenance dose produced around 15% average body-weight reduction over 68 weeks. Staying at sub-maintenance doses long term is simply not what the medicine was tested at.

Step 3: What a prescriber actually considers before adjusting your dose

Before any dose increase (or a decision to pause at a lower dose) a prescriber reviews how your body has responded so far. At nume, that review happens before every repeat order; it is not a formality. Our clinical team looks at side-effect severity, any changes in health status, and whether weight loss is tracking as expected.

The questions that matter most are whether GI symptoms are severe enough to genuinely interfere with daily life, whether they are fading or worsening, and whether staying lower is a short-term bridge or a longer-term adjustment. There is no single right answer, which is why a conversation with a prescriber, not a forum post, should drive the decision. If you have missed a dose during this process, our guidance on missed Wegovy doses explains what the clinical advice is.

For a broader overview of the full treatment, the Wegovy treatment page covers how the medicine works, who it is licensed for and what to expect from each stage.

Step 4: The cost and access reality of holding at a lower dose

Staying at a lower dose for longer has a practical financial angle too. Because each Wegovy pen contains four weekly doses at one strength, and you can see exactly how that works in our guide to Wegovy pen doses, you use one pen per month regardless of which rung of the schedule you are on. The cost per month does not fall just because you are at a lower dose. If you are weighing up private treatment costs, our Wegovy cost guide sets out what the market looks like and what transparent pricing actually covers, prescription, clinical review and delivery included.

Wegovy is a prescription-only medicine and the dose you use must be clinically agreed. Anyone selling it at any dose without a valid prescription issued after proper clinical assessment is operating outside the law. The MHRA's Yellow Card scheme lets you report suspect sellers as well as side effects, worth knowing if you ever come across offers that seem too easy or too cheap. If you have questions about your current dose or whether a slower climb is right for you, speak to our prescribers through a free consultation, with the 12pm cut-off for same-day dispatch, there is no reason to leave it until tomorrow.